血小板-淋巴细胞比值与喉鳞状细胞癌预后相关性的Meta分析

doi:10.6040/j.issn.1673-3770.0.2023.013

摘要/Abstract

摘要： 目的采用Meta分析探讨血小板-淋巴细胞比值(platelet-lymphocyte ratio, PLR)与喉鳞状细胞癌(laryngeal squamous cell carcinoma, LSCC)患者预后的相关性,为临床预测患者预后,优化治疗策略提供循证依据。方法在PubMed、Web of Science、中国知网、维普及万方等数据库检索国内外发表的PLR与LSCC预后相关性的研究,提取患者预后指标的原始数据,使用Stata12.0统计软件对数据进行Meta分析。结果共纳入14项研究,Meta分析结果显示PLR越高患者总生存期(HR=1.46,95%CI:1.34~1.58,P<0.001)、无复发生存期(HR=1.37,95%CI:1.25~1.50,P<0.001),无进展生存期(HR=1.52,95%CI:1.11~2.08,P<0.001)、无病生存期(HR=1.15,95%CI:1.04~1.27,P<0.001)、癌症特异性生存期(HR=1.24,95%CI:1.12~1.38,P<0.001)越差,差异具有统计学意义。结论 PLR值与LSCC患者预后密切相关,PLR值越高,患者预后越差,PLR值可作为评估患者预后的有效指标。

关键词: 血小板-淋巴细胞比值, 喉鳞状细胞癌, 预后, Meta分析

Abstract: Objective To investigate the correlation between platelet-lymphocyte ratio(PLR)and the prognosis of patients with laryngeal squamous cell carcinoma(LSCC)by Meta-analysis, and to predict the prognosis of patients. To provide evidence-based evidence for optimizing treatment strategies. Methods PubMed, Web of Science, CNKI, VIP and Wan fang databases were searched for studies on the correlation between PLR and the prognosis of LSCC. The raw data of prognostic indicators were extracted, and Meta-analysis was performed using Stata12.0 statistical software. Results A total of 14 studies were included. The results of Meta-analysis showed that overall survival of patients with higher PLR(HR=1.46,95%CI:1.34-1.58,P<0.001), recurrence-free survival(HR=1.37, 95%CI: 1.25-1.50, P<0.001), progression-free survival(HR=1.52, 95%CI: 1.11-2.08, P<0.001), disease-free survival(HR=1.15, 95%CI: 1.04-1.27, P<0.001), and the worse(HR=1.24, 95%CI: 1.12-1.38, P<0.001). Conclusion The prognosis of patients is closely related to PLR value. The higher the PLR value, the worse the prognosis of patients, PLR value is an effective indicator to preliminarily judge the prognosis of patients.

Key words: Platelet-lymphocyte ratio, Laryngeal squamous cell carcinoma, Prognosis, Meta-analysis

中图分类号:

R739.65

王凯健,陈雪生,王威. 血小板-淋巴细胞比值与喉鳞状细胞癌预后相关性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 67-73.

WANG Kaijian, CHEN Xuesheng, WANG Wei. A meta-analysis of the correlation between platelet-lymphocyte ratio and prognosis of laryngeal squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(3): 67-73.

参考文献

[1] 庞振文, 黄愉峰, 杨爱芳, 等. 喉癌患者术前中性粒细胞/淋巴细胞比值与淋巴结转移的相关性研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 58-62. doi: 10.6040/j.issn.1673-3770.0.2019.546 PANG Zhenwen, HUANG Yufeng, YANG Aifang, et al. Correlation between Preoperative neutrophil/lymphocyte ratio and lymph node metastasis in patients with laryngeal cancer[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(6): 58-62. doi: 10.6040/j.issn.1673-3770.0.2019.546
[2] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clin, 2016, 66(2): 115-132. doi:10.3322/caac.21338
[3] 陈慧君, 宋圣花, 董伟达, 等. 术前外周血纤维蛋白原水平对喉癌预后的影响[J]. 山东大学耳鼻喉眼学报, 2020, 34(2): 110-114. doi: 10.6040/j.issn.1673-3770.0.2019.530 CHEN Huijun, SONG Shenghua, DONG Weida, et al. Prognostic role of preoperative fibrinogen levels in patients with laryngeal squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(2): 110-114. doi: 10.6040/j.issn.1673-3770.0.2019.530
[4] Li PD, Li HY, Ding S, et al. NLR, PLR, LMR and MWR as diagnostic and prognostic markers for laryngeal carcinoma[J]. Am J Transl Res, 2022, 14(5): 3017-3027
[5] 陈慧君, 宋圣花, 周涵, 等. 血小板与淋巴细胞比值对喉癌复发的预测价值[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 106-110. doi: 10.6040/j.issn.1673-3770.1.2019.018 CHEN Huijun, SONG Shenghua, ZHOU Han, et al. Preoperative platelet-lymphocyte ratio is an independent prognostic factor for laryngeal squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(3): 106-110. doi: 10.6040/j.issn.1673-3770.1.2019.018
[6] 王川, 刘盼, 神平, 等. 外周血中性粒细胞与淋巴细胞比值以及血小板与淋巴细胞比值评估声门型喉癌患者预后的价值[J]. 中国耳鼻咽喉颅底外科杂志, 2021, 27(3): 300-304. doi: 10.11798/j.issn.1007-1520.202103091 WANG Chuan, LIU Pan, SHEN Ping, et al. Prognostic values of peripheral blood neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glottic laryngeal squamous cell carcinomas[J]. Chinese Journal of Otorhinolaryngology-Skull Base Surgery, 2021, 27(3): 300-304. doi: 10.11798/j.issn.1007-1520.202103091
[7] 王振华. 术前炎症指标预测喉癌预后的临床意义[D]. 延吉: 延边大学, 2021
[8] 张鑫婷, 汪迪, 曹萍, 等. 术前全血炎症标志物预测喉鳞状细胞癌患者预后的价值[J]. 中国眼耳鼻喉科杂志, 2022, 22(2): 131-136. doi: 10.14166/j.issn.1671-2420.2022.02.006 ZHANG Xinting, WANG Di, CAO Ping, et al. Prognostic value of whole blood inflammatory markers for patients with laryngeal squamous cell cancer undergoing surgery[J]. Chinese Journal of Ophthalmology and Otorhinolaryngology, 2022, 22(2): 131-136. doi: 10.14166/j.issn.1671-2420.2022.02.006
[9] 张曦, 赵留芳, 李静芳, 等. 术前PLR、NLR与喉鳞状细胞癌预后的相关性分析[J]. 国际检验医学杂志, 2020, 41(2): 154-158. doi: 10.3969/j.issn.1673-4130.2020.02.007 ZHANG Xi, ZHAO Liufang, LI Jingfang, et al. Correlation analysis between preoperative PLR, NLR and prognosis of laryngeal squamous cell carcinoma[J]. International Journal of Laboratory Medicine, 2020, 41(2): 154-158. doi: 10.3969/j.issn.1673-4130.2020.02.007
[10] 陶文林, 李燃, 李会磊, 等. C反应蛋白、纤维蛋白原、血小板/淋巴细胞比值与喉癌术后患者生存预后的关系[J]. 标记免疫分析与临床, 2020, 27(3): 387-392. doi:10.11748/bjmy.issn.1006-1703.2020.03.007 TAO Wenlin, LI Ran, LI Huilei, et al. The relationship between C-reactive protein, fibrinogen, platelet/lymphocyte ratio and survival prognosis in patients with postoperative laryngeal cancer[J]. Labeled Immunoassays and Clinical Medicine, 2020, 27(3): 387-392. doi:10.11748/bjmy.issn.1006-1703.2020.03.007
[11] Shen LF, Wang QY, Yu Q. The systemic immune-inflammation index and albumin as prognostic predictors in laryngeal carcinoma[J]. Nutr Cancer, 2021, 73(10): 1916-1923. doi:10.1080/01635581.2020.1812677
[12] Chen LY, Zeng H, Yang JP, et al. Survival and prognostic analysis of preoperative inflammatory markers in patients undergoing surgical resection for laryngeal squamous cell carcinoma[J]. BMC Cancer, 2018, 18(1): 816. doi:10.1186/s12885-018-4730-x
[13] Li ZL, Qu Y, Yang Y, et al. Prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in patients with laryngeal squamous cell carcinoma[J]. Clin Otolaryngol, 2021, 46(2): 395-405. doi:10.1111/coa.13689
[14] Wang J, Wang SZ, Song XM, et al. The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma[J]. Onco Targets Ther, 2016, 9: 7177-7185. doi:10.2147/OTT.S113307
[15] Cai H, Zhang ZH, Zhou YJ, et al. The prognostic value of preoperative plasma fibrinogen and neutrophil-to-lymphocyte ratio in patients with laryngeal squamous cell carcinoma[J]. Ear Nose Throat J, 2021, 100(10): 731-736. doi:10.1177/0145561320920746
[16] Hsueh C, Tao L, Zhang M, et al. The prognostic value of preoperative neutrophils, platelets, lymphocytes, monocytes and calculated ratios in patients with laryngeal squamous cell cancer[J]. Oncotarget, 2017, 8(36): 60514-60527. doi:10.18632/oncotarget.16234
[17] Chen HJ, Song SH, Zhou H, et al. Preoperative platelet-lymphocyte ratio predicts recurrence of laryngeal squamous cell carcinoma [J]. Future Oncol, 2020, 16(6): 209-217. doi: 10.2217/fon-2019-0527
[18] Mao YZ, Fu Y, Gao YF, et al. Platelet-to-lymphocyte ratio predicts long-term survival in laryngeal cancer[J]. Eur Arch Otorhinolaryngol, 2018, 275(2): 553-559. doi:10.1007/s00405-017-4849-4
[19] Sharma D, Brummel-Ziedins KE, Bouchard BA, et al. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer[J]. J Cell Physiol, 2014, 229(8): 1005-1015. doi:10.1002/jcp.24539
[20] Schlesinger M. Role of platelets and platelet receptors in cancer metastasis[J]. J Hematol Oncol, 2018, 11(1): 125. doi:10.1186/s13045-018-0669-2
[21] Viers BR, Thompson RH, Lohse CM, et al. Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renal tumors[J]. World J Urol, 2016, 34(12): 1693-1699. doi:10.1007/s00345-016-1821-7
[22] Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2016, 23(2): 646-654. doi:10.1245/s10434-015-4869-5
[23] Foss A, Muñoz-Sagredo L, Sleeman J, et al. The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells[J]. Clin Exp Metastasis, 2020, 37(1): 47-67. doi: 10.1007/s10585-019-10009-y
[24] Pan QX, Su ZJ, Zhang JH, et al. A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer[J]. Onco Targets Ther, 2015, 8: 1375-1385. doi:10.2147/OTT.S82437
[25] Cavaliere M, Bisogno A, Scarpa A, et al. Biomarkers of laryngeal squamous cell carcinoma: a review[J]. Ann Diagn Pathol, 2021, 54: 151787. doi:10.1016/j.anndiagpath.2021.151787
[26] Russo A, Franchina T, Ricciardi GRR, et al. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio(dNLR), platelet-to-lymphocyte ratio(PLR), and outcome in non small cell lung cancer(NSCLC)treated with Nivolumab or Docetaxel[J]. J Cell Physiol, 2018, 233(10): 6337-6343. doi:10.1002/jcp.26609
[27] 高梦莹, 娄卫华. 术前NLR、PLR对声门上型喉癌颈部淋巴结转移的预测价值[J]. 河南外科学杂志,2022, 28(4): 31-35

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed